Establishing Cell Therapy and Manufacturing Platforms

"Expecting to Secure a Key Research Hub in the National Life and Health Innovation Zone of China"

Excel Therapeutics, a company specializing in chemically defined media for cell and gene therapy (CGT), is collaborating with a Chinese cell therapy research institute to develop a cell therapy manufacturing platform.

Excel Therapeutics Collaborates with Chinese Cell Therapy Research Institute for Joint Cell Therapy R&D View original image

On June 30, Excel Therapeutics announced that it will pursue joint research and development of stem cell-based cell therapies with a center located in the Beidaihe Life and Health Industry Innovation Demonstration Zone in China.


This collaboration is a strategic partnership aimed at targeting the Chinese CGT market. Excel Therapeutics plans to leverage its chemically defined media technology to jointly establish standardized stem cell culture processes and a cell therapy manufacturing platform.


The Chinese cell therapy research institute involved in the collaboration operates cGMP cell manufacturing facilities and cell banks.


Through this partnership, the two institutions will work together to: ▲ develop standardized stem cell culture processes based on MSC CD AOF, ▲ develop processes for enhanced function stem cell cultures, and ▲ develop manufacturing processes for extracellular vesicles (EVs).



Kim Jongwan, Executive Director of Development Support at Excel Therapeutics, stated, "We aim to contribute to the expansion of standardized cell culture platforms based on chemically defined media in the Chinese CGT market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing